Loading company details...
Beta
Latest Form 4 (Oct 9, 2026): Joshua Reed (SVP, Chief Financial Officer): Exercise/Conversion of 9,164 shares.
Every alert includes an AI-written analysis of the filing, plus news and market context.
| Filed | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Oct 9, 2026 | Joshua Reed, SVP, Chief Financial Officer | Exercise/Conversion | 9,164 | n/a |
| Oct 9, 2026 | Anne Clem Whitaker | Grant/Award | 7,239 | n/a |
| Oct 2, 2026 | David Joseph Gaffin, EVP, CLO, Alkermes, Inc. | Sale | 2,034 | $83.5K |
| Sep 3, 2026 | David Joseph Gaffin, EVP, CLO, Alkermes, Inc. | Sale | 2,034 | $97.7K |
| Sep 1, 2026 | Craig C. Hopkinson, EVP R&D, Chief Medical Officer | Exercise/Conversion | 5,000 | $123.0K |
| Aug 17, 2026 | Christian Todd Nichols, SVP, Chief Commercial Officer | Sale | 6,912 | $340.0K |
| Aug 8, 2026 | Blair Curtis Jackson, President & CEO, Alkermes plc | Grant/Award | 93,229 | n/a |
| Aug 3, 2026 | Nancy Lynn Snyderman Md. | Exercise/Conversion | 27,948 | $1.31M |
| Aug 3, 2026 | Craig C. Hopkinson, EVP R&D, Chief Medical Officer | Exercise/Conversion | 104 | $2.0K |
| Aug 3, 2026 | David Joseph Gaffin, EVP, CLO, Alkermes, Inc. | Sale | 2,034 | $98.8K |